How do you validate cleaning processes for ADCs, monoclonal antibodies (mAbs), and highly potent active pharmaceutical ingredients (HPAPIs)? What role do degradation studies, cleaning-agent selection, and analytical testing play in reducing validation risk and supporting regulatory expectations?
Submit Your Best Content to ISPE
ISPE’s official blog, iSpeak accepts contributions from our Members and professionals in the pharma industry.